Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Merxin

  1. Events
  2. Organisers
  3. Merxin
Events from this organiser
Today

SMI.London 2025

SMI.London 2025 will continue the dialogue on soft mist inhalers (SMIs) initiated in 2023, offering a comprehensive examination of their evolving role in inhaled drug [...]

Contractors

Timesheet Portal

Clients
Legal
Contact Us

Copyright © 2025 | Hlx Life Sciences

Site by theLEAP

Go to Top